Amyotrophic Lateral Sclerosis Insights

This week's must-know community updates, latest research & events

March 26, 2025

New Report: Introduction to Cell Therapy

View the Full Report

The report is available for free online on the AllMyHealth website.

www.allmyhealth.io/reports

Would you like to sponsor our next report?

Enquire here

Latest Research

Recent research highlights the potential of using exosomal biomarkers for diagnosing and monitoring neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The study by Bi et al. (2025) focuses on LC-MS-based profiling, which could provide valuable insights into disease progression and management.

This approach suggests that analyzing exosomes, tiny vesicles released by cells, might offer a new way to track ALS and other neurodegenerative diseases. By using advanced techniques like LC-MS (liquid chromatography-mass spectrometry), researchers can identify specific biomarkers that could help in early detection and monitoring of ALS. This could lead to better disease management strategies and potentially improve patient outcomes. Further research is needed to fully explore the potential of these biomarkers in clinical settings

Clinical Trials

This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

Study of Inherited Neurological Disorders

EIM Via the Myolex MScan As an ALS Biomarker

View the full list of clinical trials →

Community News

ALSAssociationMar 19, 2025

Great news!!

ALS advocates were able to ensure Congressional medical research funding for ALS (CDMRP) remains funded at $40M.

We are beyond grateful to the incredible ALS advocates across the country who participated in our Advocacy Day of Action, including everyone who wrote letters, emailed and made phone calls to Members of Congress. Your voices made a difference for ALS. We also want to thank our staff, board members and volunteers who went to Capitol Hill last week to meet with dozens of congressional offices.

The journey isn’t over yet. Unfortunately, many research programs were cut for other diseases. We still have work to do to ensure continued support and progress in ALS research. https://bit.ly/statement-supporting

ALS CanadaMar 18, 2025

If you or another family member has tested positive for a pathogenic variant (mutation) in a gene related to #ALS, talking about potential genetic implications within the family can bring up delicate, challenging, and emotional conversations. This is why ALS Canada, in collaboration with Global Neuro YCare, created a resource to support families affected by a genetic form of ALS.

Talking to youth about ALS/MND genetics provides basic information on the genetics of ALS, support for families affected on how to approach conversations about genetics with children and youth, and genetic testing considerations for at-risk adults.

We recommend using this resource as an addition to genetic counselling, wherever you are in the world. To access the resource, visit https://bit.ly/4c3k1PN.

ALS NetworkMar 21, 2025

Use code 447 to support the California ALS Research Network Voluntary Tax Contribution Fund with your tax return and help advance critical research!

This program helps those who are battling neurodegenerative diseases like ALS. At least $250,000 must be raised to keep the program on the tax return form.

Make an impact on ALS research today by contributing $1 or more. There is no maximum contribution amount!

To learn more visit: https://ow.ly/FAwO50UY3js.